Study shows immunotherapy drug helps patients with metastatic melanoma

November 9, 2018 by Anne Doerr, Yale University
Credit: stock.adobe.com

When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. A study by Yale Cancer Center researchers published today in the Journal of Clinical Oncology (JCO) shows a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients. The study is one of the first clinical trials aimed at treating the brain metastases with this type of cancer drug.

"The study treated 23 with pembrolizumab, a drug that targets PD-1 proteins on the surface of T cells," said the study's lead author, Harriet Kluger, M.D., director of the Specialized Program of Research Excellence (SPORE) in Skin Cancer at YCC and professor of medicine at Yale School of Medicine. "Six of the trial participants (26% of the total) saw their tumors shrink or resolve, and the drug's toxicity levels were acceptable."

Importantly, added Kluger, about half of the patients were alive after two years, a rate similar to that of patients in other who had metastatic melanoma without tumors and were given anti-PD-1 drugs.

"One of the big messages of our study is that patients with who had a response to this drug elsewhere in the body also had a response in the brain," she said. "This suggests that for some patients, metastases can be treated similarly in the brain and the body, particularly if the are small and not located in critical sites. However, caution should be taken with this approach, and a multidisciplinary clinical team including close involvement of neurosurgeons and therapeutic radiologists is necessary in case no shrinkage is seen."

Kluger noted that another recently reported trial for patients with untreated brain melanoma metastases who were given two immunotherapy drugs achieved a significantly higher rate of response. Results published in the New England Journal of Medicine showed a clinical benefit of 57% among 94 patients who were treated with another PD-1 inhibitor plus a checkpoint inhibitor that targets the CTLA-4 protein on the surface of T cells.

Together, these latest clinical findings suggest that melanoma patients with brain metastases should be given a combination of the two types of checkpoint inhibitors, if the patients are healthy enough for this aggressive regimen, Kluger said. Treatment with a PD-1 inhibitor is appropriate if the patients are not so robust or perhaps if the brain tumors are tiny and not producing symptoms of disease, she said.

Until recently, people with brain metastases were typically excluded from clinical trials of novel therapies. One reason, Kluger said, is because researchers found it hard to track which drugs could penetrate the blood-brain barrier (the special vasculature that protects the brain and often keeps out cancer drugs). Clinicians also worried that if the drugs didn't work, they would lose control of the disease. With improvements in drugs, brain imaging and radiation treatments, researchers now have become more comfortable with starting trials for brain metastases, said Kluger.

Major questions remain, however, about immunotherapy for brain , she noted. Scientists don't know how well these drugs penetrate the blood-brain barrier, which is disrupted in tumors. Scientists also don't know whether the drug actually gets into the brain or whether it stimulates immune cells that then enter the brain, Kluger pointed out. Researchers do know that the collection of immune and vascular cells in the area around the and within the tumor, known as the tumor microenvironment, may behave quite differently in the brain than elsewhere in the body, which can change how (and if) a drug works.

The YCC clinicians are following up with another trial that will combine pembrolizumab with bevacizumab, a that aims to stop the growth of blood vessels that supply tumors. The hope is that this combination will aid in reducing complications that patients may suffer from radiation before they are given immunotherapy. The investigators expect to release an initial report on the follow-up study in 2019.

Explore further: Combination immunotherapy shrinks melanoma brain metastases

More information: Harriet M. Kluger et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial, Journal of Clinical Oncology (2018). DOI: 10.1200/JCO.18.00204

Related Stories

Combination immunotherapy shrinks melanoma brain metastases

August 22, 2018
Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas ...

In melanoma, radiosurgery may combine well with immunotherapy, especially PD-1 inhibitors

June 25, 2018
Doctors often treat melanoma with drugs that unblind the immune system to cancer. And brain metastases associated with melanoma are often treated with precisely targeted radiation known as radiosurgery. Now a University of ...

Immunotherapy doubles survival rates for patients with melanoma brain metastases

July 12, 2018
Cancer immunotherapies and targeted therapy have revolutionized how clinicians take care of patients with advanced skin cancer and have led to long lasting treatment responses for many of them. However, little is known about ...

For aggressive breast cancer in the brain, researchers clarify immune response

April 17, 2018
Once it has begun to spread in the body, approximately half of patients with an aggressive breast cancer type will develop cancer in the brain. Researchers at the University of North Carolina Lineberger Comprehensive Cancer ...

Two combination therapies shrink melanoma brain metastases in more than half of patients

June 5, 2017
High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have been largely left out of recent treatment progress - those whose disease has spread ...

Immune and targeted therapies with radiation therapy improves outcomes for melanoma brain metastases patients

September 21, 2016
Brain metastases are one of the most common complications of advanced melanoma, requiring multidisciplinary management. Patients who are diagnosed with these metastases have an expected median survival of only 4 to 5 months. ...

Recommended for you

Researchers identify a mechanism that fuels cancer cells' growth

November 14, 2018
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified sodium glucose transporter 2, or SGLT2, as a mechanism that lung cancer cells can utilize to obtain glucose, which is key to their survival and promotes ...

A new approach to detecting cancer earlier from blood tests: study

November 14, 2018
Cancer scientists led by principal investigator Dr. Daniel De Carvalho at Princess Margaret Cancer Centre have combined "liquid biopsy", epigenetic alterations and machine learning to develop a blood test to detect and classify ...

New antibody breakthrough to lead the fight against cancer

November 14, 2018
Scientists at the University of Southampton have developed a new antibody that could hold the key to unlocking cancer's defence against the body's immune system.

Photoacoustic imaging may help doctors detect ovarian tumors earlier

November 14, 2018
Ovarian cancer claims the lives of more than 14,000 in the U.S. each year, ranking fifth among cancer deaths in women. A multidisciplinary team at Washington University in St. Louis has found an innovative way to use sound ...

Solving the mystery of NPM1 in acute myeloid leukemia

November 13, 2018
Although it has long been recognized that mutations of gene NPM1 play an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.

Cognitive decline—radiation—brain tumor prevented by temporarily shutting down immune response

November 13, 2018
Treating brain tumors comes at a steep cost, especially for children. More than half of patients who endure radiation therapy for these tumors experience irreversible cognitive decline, a side-effect that has particularly ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.